Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Term (2-Year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Galantamine (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use

Most Recent Events

14 Oct 2021 This trial has been completed in France (End Date: 20 May 2012), according to European Clinical Trials Database record.
24 Jun 2013 Results presented at the 11th World Congress of Biological Psychiatry.
24 Jun 2013 Primary endpoint 'Mini-Mental-State-Examination' has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com